Schrödinger Intrinsic Stock Value – SCHRÖDINGER Reports Q2 Earnings for FY2023 on August 2nd, 2023
August 7, 2023
🌥️Earnings Overview
On August 2, 2023, SCHRÖDINGER ($NASDAQ:SDGR) reported its second-quarter results for FY2023, showing a total revenue decrease of 8.5% year-over-year to USD 35.2 million, while net income increased by an impressive 109.0% compared to the same period the previous year at USD 4.3 million.
Market Price
On Wednesday, August 2nd, 2023, SCHRÖDINGER released their second quarter earnings report for the fiscal year of 2023. At the opening of trading, SCHRÖDINGER stock opened at $51.0, but by the end of the day had closed at $50.2, representing a decrease of 4.0% from their previous closing price of $52.3. The release of the earnings report may have contributed to the decrease in stock value, as analysts and investors alike had mixed reactions to the report. It remains to be seen how SCHRÖDINGER’s stock will perform over the course of the fiscal year, and whether the earnings report will positively or negatively affect their long-term performance. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Schrödinger. More…
| Total Revenues | Net Income | Net Margin |
| 193.79 | 66.35 | -3.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Schrödinger. More…
| Operations | Investing | Financing |
| -104.84 | 258.84 | 6.2 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Schrödinger. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 841.57 | 230.34 | 8.51 |
Key Ratios Snapshot
Some of the financial key ratios for Schrödinger are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 26.8% | – | -85.8% |
| FCF Margin | ROE | ROA |
| -59.4% | -17.3% | -12.4% |
Analysis – Schrödinger Intrinsic Stock Value
At GoodWhale, we have analyzed SCHRÖDINGER’s financials and have calculated the fair value of its shares to be around $66.0 through our proprietary Valuation Line. Our analysis indicates that the stock is currently trading at $50.2 which is significantly below the fair value, representing an undervaluation of 23.9%. This presents a great opportunity for investors to acquire SCHRÖDINGER stock at a discounted price. More…
Peers
Its competitors are Global Health Ltd, CardioComm Solutions Inc, and Simulations Plus Inc.
– Global Health Ltd ($ASX:GLH)
Global Health Ltd is a healthcare company with a focus on providing affordable and accessible healthcare products and services to underserved communities worldwide. The company has a market capitalization of 14.19 million as of 2022 and a return on equity of -19.3%. Global Health Ltd’s mission is to improve the health and wellbeing of people around the world by providing affordable and accessible healthcare products and services. The company’s products and services include primary care, maternal and child health, sexual and reproductive health, and non-communicable disease prevention and treatment. Global Health Ltd operates in over 50 countries and has a presence in more than 100 communities worldwide.
– CardioComm Solutions Inc ($TSXV:EKG)
CardioComm Solutions Inc is a medical device company that develops, manufactures and markets proprietary software solutions for the diagnosis and monitoring of cardiac patients. It has a market cap of 2.26M as of 2022 and a return on equity of -59.73%. The company’s products are used in hospitals, clinics and other healthcare settings around the world.
– Simulations Plus Inc ($NASDAQ:SLP)
Simulations Plus Inc. is a publicly traded company with a market capitalization of 811.3 million as of 2022. The company has a return on equity of 5.24%. Simulations Plus Inc. is a leading provider of simulation and modeling software for the pharmaceutical, biotechnology, and medical device industries. The company’s software is used by scientists to predict the behavior of complex systems, such as the human body, in order to improve the safety and efficacy of new drugs and medical devices.
Summary
Schrödinger reported its earnings for the second quarter of FY2023, with total revenue dropping 8.5% year over year to USD 35.2 million. Net income increased 109.0%, however, reaching USD 4.3 million. This caused the company’s stock price to move down the same day.
From an investing standpoint, Schrödinger had a mixed quarter, with increases in net income but a decline in total revenue. Investors should watch for future signs of growth or decline in both revenue and profits to gain a better understanding of the company’s financial situation.
Related Posts
Recent Posts
